XOMA : NASDAQ : Health Care
$4.59 | %
Today's Range: 4.56 - 4.72
Avg. Daily Volume: 87800.0
01/20/17 - 4:00 PM ET

Financial Analysis


XOMA CORP's gross profit margin for the third quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. XOMA CORP has weak liquidity. Currently, the Quick Ratio is 0.93 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has decreased by 6.84% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)0.642.07
EBITDA ($mil)-11.91-20.7
EBIT ($mil)-12.09-21.12
Net Income ($mil)-12.53-0.48


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)20.6232.05
Total Assets ($mil)24.6979.03
Total Debt ($mil)45.2248.59
Equity ($mil)-31.19-29.19


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin-1875.12-148.26
EBITDA Margin-1875.11-998.11
Operating Margin-1904.25-1018.23
Sales Turnover2.160.15
Return on Assets-43.32-67.41
Return on Equity0.00.0
Debt Q3 FY16 Q3 FY15
Current Ratio0.981.26
Debt/Capital3.222.51
Interest Expense0.981.03
Interest Coverage-12.31-20.52


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)6.035.94
Div / share0.00.0
EPS-2.00.0
Book value / share-5.17-4.91
Institutional Own % n/a n/a
Avg Daily Volume158206.0865831.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
XOMA NM Peers 34.33   XOMA NM Peers 27.22

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

XOMA's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

XOMA's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
XOMA NM Peers 24.82   XOMA NA Peers 0.41

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

XOMA's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
XOMA NM Peers 11.43   XOMA 82.36 Peers 3.61

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

XOMA's P/B is negative making this valuation measure meaningless.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

XOMA is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
XOMA 0.53 Peers 136.62   XOMA 358.34 Peers 532.92

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

XOMA is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

XOMA significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades